Biomarkers: Population Screening and Risk-Stratification

I. Ratjen; R. S. Vasan; W. Lieb

doi:10.1016/B978-0-12-809657-4.64154-6

Biomarkers: Population Screening and Risk-Stratification

I. Ratjen, R. S. Vasan, W. Lieb

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Biomarkers are increasingly considered as instruments for population screening and cardiovascular risk stratification. In addition to meeting key requirements that apply to all biomarkers, screening biomarkers should be able to identify—in a large sample screened—those individuals who are currently free of cardiovascular disease (CVD) but who are at high risk of developing CVD in the future. Ideally, screening biomarkers capture the disease process at an early stage, for example, by detecting subclinical changes that predispose to clinically overt CVD. In order to improve risk stratification beyond established risk factors, novel biomarkers should improve the estimation of absolute disease risks and the reclassification of individuals in more appropriate risk categories.

Original language	English (US)
Title of host publication	Encyclopedia of Cardiovascular Research and Medicine
Publisher	Elsevier
Pages	323-333
Number of pages	11
Volume	1-4
ISBN (Electronic)	9780128051542
ISBN (Print)	9780128096574
DOIs	https://doi.org/10.1016/B978-0-12-809657-4.64154-6
State	Published - Jan 1 2017
Externally published	Yes

Keywords

Biomarkers
C-reactive protein
Cardiovascular disease
Genetics
Imaging biomarkers
Population screening

ASJC Scopus subject areas

General Medicine

Access to Document

10.1016/B978-0-12-809657-4.64154-6

Cite this

@inbook{bb10f46db0b2405588bd7510b6ac81ea,

title = "Biomarkers: Population Screening and Risk-Stratification",

abstract = "Biomarkers are increasingly considered as instruments for population screening and cardiovascular risk stratification. In addition to meeting key requirements that apply to all biomarkers, screening biomarkers should be able to identify—in a large sample screened—those individuals who are currently free of cardiovascular disease (CVD) but who are at high risk of developing CVD in the future. Ideally, screening biomarkers capture the disease process at an early stage, for example, by detecting subclinical changes that predispose to clinically overt CVD. In order to improve risk stratification beyond established risk factors, novel biomarkers should improve the estimation of absolute disease risks and the reclassification of individuals in more appropriate risk categories.",

keywords = "Biomarkers, C-reactive protein, Cardiovascular disease, Genetics, Imaging biomarkers, Population screening",

author = "I. Ratjen and Vasan, {R. S.} and W. Lieb",

year = "2017",

month = jan,

day = "1",

doi = "10.1016/B978-0-12-809657-4.64154-6",

language = "English (US)",

isbn = "9780128096574",

volume = "1-4",

pages = "323--333",

booktitle = "Encyclopedia of Cardiovascular Research and Medicine",

publisher = "Elsevier",

}

TY - CHAP

T1 - Biomarkers

T2 - Population Screening and Risk-Stratification

AU - Ratjen, I.

AU - Vasan, R. S.

AU - Lieb, W.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Biomarkers are increasingly considered as instruments for population screening and cardiovascular risk stratification. In addition to meeting key requirements that apply to all biomarkers, screening biomarkers should be able to identify—in a large sample screened—those individuals who are currently free of cardiovascular disease (CVD) but who are at high risk of developing CVD in the future. Ideally, screening biomarkers capture the disease process at an early stage, for example, by detecting subclinical changes that predispose to clinically overt CVD. In order to improve risk stratification beyond established risk factors, novel biomarkers should improve the estimation of absolute disease risks and the reclassification of individuals in more appropriate risk categories.

AB - Biomarkers are increasingly considered as instruments for population screening and cardiovascular risk stratification. In addition to meeting key requirements that apply to all biomarkers, screening biomarkers should be able to identify—in a large sample screened—those individuals who are currently free of cardiovascular disease (CVD) but who are at high risk of developing CVD in the future. Ideally, screening biomarkers capture the disease process at an early stage, for example, by detecting subclinical changes that predispose to clinically overt CVD. In order to improve risk stratification beyond established risk factors, novel biomarkers should improve the estimation of absolute disease risks and the reclassification of individuals in more appropriate risk categories.

KW - Biomarkers

KW - C-reactive protein

KW - Cardiovascular disease

KW - Genetics

KW - Imaging biomarkers

KW - Population screening

UR - http://www.scopus.com/inward/record.url?scp=85159025938&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85159025938&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-809657-4.64154-6

DO - 10.1016/B978-0-12-809657-4.64154-6

M3 - Chapter

AN - SCOPUS:85159025938

SN - 9780128096574

VL - 1-4

SP - 323

EP - 333

BT - Encyclopedia of Cardiovascular Research and Medicine

PB - Elsevier

ER -

Biomarkers: Population Screening and Risk-Stratification

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this